

Department of Health and Human Services
National Institutes of Health
National Institute of Neurological Disorders and Stroke

**National Advisory Neurological Disorders and Stroke (NANDS) Council
218th Meeting**

February 1 and 2, 2023

[Watch a live broadcast on the NIH Videocast Website](#)

AGENDA

OPEN SESSION

1:00 p.m.	I. Call to Order and Opening Remarks Dr. Walter Koroshetz, Chairperson Director, NINDS
1:05 p.m.	II. Report of the Director, Division of Extramural Activities, NINDS Dr. Robert Finkelstein Associate Director, Division of Extramural Activities Executive Secretary, NANDS Council A. Consideration of September 7-8 2022, Meeting Minutes B. Confirmation of Dates for Future Council Meetings Wed & Thurs, May 31, 2023 – June 1, 2023 Wed & Thurs, September 6-7, 2023 Wed & Thurs, February 14-15, 2024 Wed & Thurs, May 15-16, 2024 Wed & Thurs, September 4-5, 2024 C. Other Items Expedited Review Process Extramural Announcements-
1:15 p.m.	III. Report of the Director, NINDS Dr. Walter Koroshetz
1:35 p.m.	IV. Discussion of Director's Report
2:00 p.m.	V. Approval of Council Operating Procedure
2:15 p.m.	VI. HEAL Initiative Update and Council Discussion Dr. Linda Porter Program Director, Office of Pain Policy

	Dr. Michael Oshinsky Program Director, Division of Neuroscience
3:00 p.m.	BREAK
3:15 p.m.	VII. Amyotrophic Lateral Sclerosis (ALS) Strategic Planning Discussion of Strategic Priorities Dr. Amelie Gubitz Program Director, Division of Neuroscience Dr. Rita Sattler Professor of Translational Neuroscience, Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center Dr. Layne Oliff Person Living with ALS, NEALS Research Ambassador/ The International Alliance of ALS/MND Associations Ms. Ellyn Phillips Caregiver, Board Chair Emeritus ALS Association Greater Philadelphia Chapter Mr. Dan Doctoroff Person Living with ALS, former Chairman and CEO, Sidewalk Labs, Founder and Board of Directors, Target ALS Update from the FDA – ACT for ALS activities Dr. Jacqueline Corrigan-Curay Principal Deputy Center Director, Center for Drug Evaluation and Research, FDA
4:30 p.m.	VIII. Initiatives for Concept Clearance
5:30 p.m.	IX. Adjournment (time is approximate)

February 2, 2023

CLOSED SESSION

This portion of the meeting is being closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

1:00 p.m.	X. Review of Conflict of Interest, Confidentiality, and Council Procedures; Council Consideration of Pending Applications Dr. Robert Finkelstein
-----------	--

	Executive Secretary, NANDS Council
5:00 p.m.	Adjournment (*This time is tentative.)